Intradiskal methylene blue treatment for diskogenic low back pain

Area of Science:

• Orthopedics
• Pain Management
• Regenerative Medicine

Background:

• Low back pain is a primary cause of disability, with intervertebral disc issues being a common source.
• Previous treatments for discogenic pain have yielded limited success.
• Emerging research suggests potential benefits of methylene blue injections for pain and function.

Purpose of the Study:

• To evaluate the effectiveness of intradiskal methylene blue injections in patients diagnosed with diskogenic low back pain.
• To assess changes in pain and function following the procedure.

Main Methods:

• A prospective trial involving patients diagnosed with diskogenic pain via diskography.
• Patients received a single intradiskal injection of methylene blue.
• Pain (Visual Analog Scale) and function (Oswestry Disability Index) were measured at baseline and at 1, 2, and 6 months post-treatment.

Main Results:

• Sixteen patients completed the trial, receiving one to three levels of injection.
• Categorical success rates for pain (VAS) at 1, 2, and 6 months were 25%, 21%, and 25%, respectively.
• Categorical success rates for function (ODI) at 1, 2, and 6 months were 25%, 21%, and 33%, respectively. Overall success rates ranged from 19% to 25%.

Conclusions:

• This study indicates that intradiskal methylene blue injections did not achieve overall clinical success in patients with diskogenic low back pain.
• The small sample size limits definitive conclusions.
• Further investigation is warranted to determine the potential role of methylene blue in managing chronic low back pain.